Approved drugs screening against the nsP1 capping enzyme of Venezuelan equine encephalitis virus using an immuno-based assay.
Animals
Antiviral Agents
/ pharmacology
Chlorocebus aethiops
Drug Approval
Encephalitis Virus, Venezuelan Equine
/ drug effects
Enzyme-Linked Immunosorbent Assay
High-Throughput Screening Assays
Humans
Inhibitory Concentration 50
RNA Caps
Vero Cells
Viral Nonstructural Proteins
/ antagonists & inhibitors
Virus Replication
/ drug effects
Alphavirus
Antivirals
Approved drugs
Guanylylation
HT screening
mRNA capping
Journal
Antiviral research
ISSN: 1872-9096
Titre abrégé: Antiviral Res
Pays: Netherlands
ID NLM: 8109699
Informations de publication
Date de publication:
03 2019
03 2019
Historique:
received:
22
10
2018
revised:
28
11
2018
accepted:
09
01
2019
pubmed:
15
1
2019
medline:
14
3
2020
entrez:
15
1
2019
Statut:
ppublish
Résumé
Alphaviruses such as the Venezuelan equine encephalitis virus (VEEV) are important human emerging pathogens transmitted by mosquitoes. They possess a unique viral mRNA capping mechanism catalyzed by the viral non-structural protein nsP1, which is essential for virus replication. The alphaviruses capping starts by the methylation of a GTP molecule by the N7-guanine methyltransferase (MTase) activity; nsP1 then forms a covalent link with m
Identifiants
pubmed: 30639438
pii: S0166-3542(18)30645-4
doi: 10.1016/j.antiviral.2019.01.003
pii:
doi:
Substances chimiques
Antiviral Agents
0
RNA Caps
0
Viral Nonstructural Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
59-69Informations de copyright
Copyright © 2019 Elsevier B.V. All rights reserved.